Daneng Li, M.D.

(877) 460-4673
Daneng Li, M.D.
Medical Oncologist
Clinical Expertise
  • Liver Tumors
  • Gallbladder Cancer
  • Gastrointestinal Cancers
  • Gastrointestinal Carcinoid Tumors
  • Pancreatic Cancer
  • Geriatric Oncology
  • Bile Duct Cancer
Research Area
  • Liver Tumors
  • Neuroendocrine Tumors
  • Cancer and Aging
Academic Appointments
  • Associate Professor, Department of Medical Oncology & Therapeutics Research
  • Co-Director, Neuroendocrine Tumor Program
Clinical Teams
Bile Duct Cancer
Colorectal Cancer
Gallbladder Cancer
Gastrointestinal Cancers
Gastrointestinal Carcinoid Tumors
Hereditary Colorectal Cancer Multidisciplinary Program
Liver Cancers and Liver Tumors
Medical Oncology & Therapeutics Research
Pancreatic Cancer
Small Intestine Cancer
Stomach (Gastric) Cancer
Research Teams
Liver Cancer
Neuroendocrine Tumors
Developmental Cancer Therapeutics Program (CCC)

Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope.

Dr. Li earned his undergraduate degree from The Ohio State University in Columbus, Ohio, graduating summa cum laude. He then went on to receive his medical doctorate from Weill Cornell Medical College in New York, before pursuing an internship and residency in internal medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center. He then completed a hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City.

Board certified in internal medicine and medical oncology, Dr. Li serves on several national committees focused on his specialty tumor types. He has authored several publications in the peer reviewed literature, and has presented his work nationally.

Location

Education & Experience

Board Certifications

  • 2015, Diplomate, American Board of Medical Oncology

Degrees

  • 2009, M.D., Weill Cornell Medical College, New York, NY
  • 2005, B.S., molecular genetics, summa cum laude, The Ohio State University, Columbus, OH

Fellowship

  • 2012-2015, Fellow in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Residency

  • 2009-2012, Internship and Residency in Internal Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY

Professional Experience

  • 2022–Present, Associate Professor, Department of Medical Oncology & Experimental Therapeutics, City of Hope National Medical Center
  • 2021–Present, Assistant Professor, Department of Medical Oncology & Experimental Therapeutics, City of Hope National Medical Center
  • 2015–2021, Assistant Clinical Professor, Department of Medical Oncology & Experimental Therapeutics, City of Hope National Medical Center

Awards & Memberships

Awards

  • 2023 Blue Faery Award for Excellence in Liver Cancer Research

Memberships

  • American Society of Clinical Oncology
  • Cancer and Aging Research Group
  • Phi Beta Kappa
  • International Society of Geriatric Oncology
  • Alliance Cancer in the Elderly Committee
  • SWOG Gastrointestinal Cancer Committee
  • NANETS Research Committee

Publications

  • Li D, Crook CJ, Zhang YH, Ruel N, Ituarte PHG, Kessler J, Lee A, Singh D, Singh G. Racial/ethnic disparities in hepatocellular carcinoma treatment and survival: an analysis of the California Cancer Registry. Cancer Treat Res Commun. 2025 Oct 4;45:101016. doi: 10.1016/j.ctarc.2025.101016. PMID: 41072351
  • Yang HY, Li X, Hoogland AI, Welniak TL, Rodriguez Y, Carpenter KM, Fischer SM, Kinney AY, Li D, Nguyen O, Rotroff DM, Mariam A, Berry DL, Extermann M, Kim R, Lee KT, Jim HSL. Acute Change in Perceived Cognitive Performance Across Different Age Groups Following First Chemotherapy Infusion in Female Patients With Breast Cancer. Psychooncology. 2025 Oct;34(10):e70288. doi: 10.1002/pon.70288. PMID: 41058041
  • Tai D, Latif K, Shah P, Park D, Crook C, Guzman S, Brar G, Li D, Castillo D; Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA. Front Oncol. 2025 Aug 14;15:1622984. doi: 10.3389/fonc.2025.1622984. eCollection 2025. PMID: 40896428
  • Dominguez DA, Wong P, Chen YJ, Singh GP, Fong Y, Li D, Ituarte PHG, Melstrom LG. ASO Visual Abstract: Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma-Evaluation of SWOG S0809 with a Large National Database. Ann Surg Oncol. 2025 May 17. doi: 10.1245/s10434-024-15260-6. PMID: 40382450
  • Plummer R, Sodergren MH, Hodgson R, Ryan BM, Raulf N, Nicholls JP, Reebye V, Voutila J, Sinigaglia L, Meyer T, Pinato DJ, Sarker D, Basu B, Blagden S, Cook N, Jeffrey Evans TR, Yachnin J, Chee CE, Li D, El-Khoueiry A, Diab M, Huang KW, Pai M, Spalding D, Talbot T, Noel MS, Keenan B, Mahalingam D, Song MS, Grosso M, Arnaud D, Auguste A, Zacharoulis D, Storkholm J, McNeish I, Habib R, Rossi JJ, Habib NA. TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors. Cell Rep Med. 2025 Apr 15;6(4):102041. doi: 10.1016/j.xcrm.2025.102041. Epub 2025 Mar 31. PMID: 40168999
  • Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne AM, Cotter C, Badhrinarayanan S, Wang Y, Yin A, Edubilli TR, Mahrus S, Secrest MH, Shemesh CS, Yu N, Hack SP, Cha E, Gane E. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study. Lancet Oncol. 2025 Jan 21:S1470-2045(24)00679-X. doi: 10.1016/S1470-2045(24)00679-X. Epub ahead of print. PMID: 39855251
  • Macarulla T, Ren Z, Chon HJ, Park JO, Kim JW, Pressiani T, Li D, Zhukova L, Zhu AX, Chen MH, Hack SP, Wu S, Liu B, Guan X, Lu S, Wang Y, El-Khoueiry AB. Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. J Clin Oncol. 2025 Feb 10;43(5):545-557. doi: 10.1200/JCO.24.00337. Epub 2024 Oct 18. PMID: 39423355
  • Finn RS, Galle PR, Ducreux M, Cheng AL, Reilly N, Nicholas A, Hernandez S, Ma N, Merle P, Salem R, Li D, Breder V. Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150. Liver Cancer. 2024 Jun 21;13(6):655-668. doi: 10.1159/000539897. eCollection 2024 Dec. PMID: 39687036
  • Li D, Crook C, Chung V, Brar G, Fakih M, Barzi A, Melstrom L, Singh G, Fong Y, Frankel P, Raoof M. Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases. Future Oncol. 2024 Sep 12:1-11. doi: 10.1080/14796694.2024.2394013 PMID: 39263892 DOI: 10.1080/14796694.2024.2394013
  • Cabrera Chien L, Sun CL, Kim H, Uranga C, Soto-Perez-de-Celis E, Burhenn P, Charles K, Vazquez J, Roberts E, Yu W, Kim JY, Lau C, Sentovich S, Dorff TB, Sedrak MS, Katheria V, Hurria A, Dale W, Li D. Geriatric Assessment-driven INterventions among Hospitalized older adults with cancer (GAIN-HOSP), a prospective pilot study. J Geriatr Oncol. 2024 Sep 12:102063. doi: 10.1016/j.jgo.2024.102063. Online ahead of print. PMID: 39271412
  • Mahuron KM, Limbach KE, Hernandez MC, Ituarte PHG, Li D, Kessler J, Singh G; Liver Resection for Gastroenteropancreatic Neuroendocrine Tumors with Extrahepatic Disease. J Clin Med. 2024 Aug 23;13(17):4983. doi: 10.3390/jcm13174983. PMID: 39274193

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
4.7
Provider explain in way you understand
4.7
Provider listen carefully to you
4.7
Know important info medical history
4.7
Show respect for what you say
4.7
Rate provider 0-10
4.6
Spend enough time with you
4.5
Recommend this provider office
01/26/26
City of Hope is the best place to be for everyone diagnosed with Neuroendocrine cancer. - Verified patient
01/26/26
Dr Li is a renound NET specialist who I thoroughly respect. I feel lucky to have him head my medical team and treatment decisions. - Verified patient
01/20/26
Good - Verified patient
01/19/26
[...] Dr. Li has poor bedside manner and communication skills. He will answer questions but does not expand or elaborate like our other COH doctors. - Verified patient
01/19/26
Dr. Li is a man of few words. Never calls to explain test results, even for PET scans to determine treatment eligibility. Says he will call if there is a problem. Our other COH doctors phone after significant procedures or developments. [...] visit was a routine monthly procedure. I had taken a PET scan the previous week, but the results weren't in yet. Asked Dr. Li if we could schedule a follow-up visit to discuss results when available. He said that wasn't necessary. If the scan results were positive, I could just let him know If I want to proceed to the next treatment. No discussion of what that would be like, common side effects, his experience with similar patients, quality of life considerations, etc. [...] I never did hear from Dr. Li. - Verified patient